Z. Man

4.8k total citations · 1 hit paper
20 papers, 910 citations indexed

About

Z. Man is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, Z. Man has authored 20 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 17 papers in Orthopedics and Sports Medicine and 9 papers in Molecular Biology. Recurrent topics in Z. Man's work include Bone health and treatments (17 papers), Bone health and osteoporosis research (17 papers) and Bone Metabolism and Diseases (7 papers). Z. Man is often cited by papers focused on Bone health and treatments (17 papers), Bone health and osteoporosis research (17 papers) and Bone Metabolism and Diseases (7 papers). Z. Man collaborates with scholars based in United States, Belgium and France. Z. Man's co-authors include Steven Boonen, Steven R. Cummings, Kurt Lippuner, Dennis M. Black, Jane A. Cauley, Ian R. Reid, Ping‐Chung Leung, P. Lakatos, Felicia Cosman and Christina Bucci‐Rechtweg and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Journal of Bone and Mineral Research.

In The Last Decade

Z. Man

18 papers receiving 873 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

2011 477 citations Dennis M. Black, Ian R. Reid et al. Journal of Bone and Mineral Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Z. Man United States	9	812	676	332	179	52	20	910
Jayanti Gupta United States	3	902 1.1×	781 1.2×	301 0.9×	181 1.0×	78 1.5×	5	1.0k
Anne de Papp United States	8	568 0.7×	412 0.6×	126 0.4×	202 1.1×	80 1.5×	12	685
Dietrich Wenderoth United Kingdom	9	825 1.0×	649 1.0×	373 1.1×	158 0.9×	36 0.7×	13	948
P. Chen United States	8	493 0.6×	259 0.4×	155 0.5×	188 1.1×	32 0.6×	8	646
Jane Orgee United Kingdom	7	459 0.6×	376 0.6×	109 0.3×	130 0.7×	43 0.8×	10	577
Garth Beinart United States	6	255 0.3×	200 0.3×	151 0.5×	162 0.9×	43 0.8×	9	510
Mika Tsujimoto Japan	10	293 0.4×	227 0.3×	116 0.3×	108 0.6×	23 0.4×	16	471
E Boling United States	5	429 0.5×	299 0.4×	237 0.7×	55 0.3×	27 0.5×	7	590
Annalisa Avanzati Italy	10	194 0.2×	289 0.4×	85 0.3×	56 0.3×	59 1.1×	10	466
Rodolfo Argueta United States	7	222 0.3×	220 0.3×	109 0.3×	86 0.5×	47 0.9×	9	537

Countries citing papers authored by Z. Man

Since Specialization

Citations

This map shows the geographic impact of Z. Man's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z. Man with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z. Man more than expected).

Fields of papers citing papers by Z. Man

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z. Man. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z. Man. The network helps show where Z. Man may publish in the future.

Co-authorship network of co-authors of Z. Man

This figure shows the co-authorship network connecting the top 25 collaborators of Z. Man. A scholar is included among the top collaborators of Z. Man based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z. Man. Z. Man is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papapoulos, Socrates E., Michael R. McClung, Nathalie Franchimont, et al.. (2013). DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO). 24. 1 indexed citations

Chapurlat, R., Socrates E. Papapoulos, Jacques P. Brown, et al.. (2012). Treatment of postmenopausal women with osteoporosis for six years with denosumab : three-year results from the freedom extension. Open Repository and Bibliography (University of Liège). 1 indexed citations

McClung, Michael R., José Zanchetta, Artur Racewicz, et al.. (2012). Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporosis International. 24(1). 293–299. 21 indexed citations

McClung, Michael R., Claude-Laurent Benhamou, Z. Man, et al.. (2012). A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data. Calcified Tissue International. 92(1). 59–67. 7 indexed citations

Mellström, Dan, Jacques P. Brown, Henry G. Bone, et al.. (2012). Denosumab treatment for 6years in postmenopausal women with osteoporosis: The first 3years of the freedom extension. Bone. 50. S53–S54.

Black, Dennis M., Ian R. Reid, Steven Boonen, et al.. (2012). EFFECT OF 6-YEAR TREATMENT OF OSTEOPOROSIS WITH ZOLEDRONIC ACID 5MG (ACLASTA) COMPARED WITH THE 3-YEAR-TREATMENT, RESULTS OF EXTENDED HORIZON PFT STUDY. SHILAP Revista de lepidopterología. 15(1). 40–41. 1 indexed citations

Papapoulos, Socrates E., Z. Man, Dan Mellström, et al.. (2011). FIVE-YEAR DENOSUMAB TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE FIRST TWO YEARS OF THE FREEDOM TRIAL EXTENSION. Data Archiving and Networked Services (DANS). 9 indexed citations

Black, Dennis M., Ian R. Reid, Steven Boonen, et al.. (2011). The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research. 27(2). 243–254. 477 indexed citations breakdown →

Boonen, Steven, Jonathan D. Adachi, Z. Man, et al.. (2011). Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk. The Journal of Clinical Endocrinology & Metabolism. 96(6). 1727–1736. 157 indexed citations

10.

Black, Dennis M., Ian R. Reid, Jane A. Cauley, et al.. (2011). The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Bone. 48. S91–S91. 49 indexed citations

11.

Chapurlat, R., Socrates E. Papapoulos, Henry G. Bone, et al.. (2010). Long-term denosumab treatment of postmenopausal women with osteoporosis: results from the first year extension study of the FREEDOM trial. Open Repository and Bibliography (University of Liège). 2 indexed citations

12.

Cauley, Jane A., Dennis M. Black, Steven Boonen, et al.. (2010). Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. Journal of Bone and Mineral Research. 26(5). 984–992. 26 indexed citations

13.

Eastell, Richard, Thomas Lang, Steven Boonen, et al.. (2009). Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis International. 21(7). 1277–1285. 38 indexed citations

14.

Recker, Robert R., José Zanchetta, C. Mautalén, et al.. (2009). Safety and efficacy of 36 months treatment of postmenopausal osteoporotic women with PTH (1–84). Bone. 44. S431–S431.

15.

Black, Dennis M., Richard Eastell, Felicia Cosman, et al.. (2009). Effect of once-yearly zoledronic acid 5 mg on ‘Super Six’ non-vertebral fractures. Bone. 44. S429–S429. 1 indexed citations

16.

Eastell, Richard, Dennis M. Black, Jane A. Cauley, et al.. (2007). Effect of once-yearly infusion of zoledronic acid 5 mg in postmenopausal women with osteoporosis. 14. 2 indexed citations

17.

Delmas, Pierre D., C.L. Benhamou, Z. Man, et al.. (2007). Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International. 19(7). 1039–1045. 48 indexed citations

18.

Zhou, Jin, et al.. (2007). Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia. Haematologica. 92(9). e82–e84. 2 indexed citations

19.

Delmas, Pierre D., Michael R. McClung, José Zanchetta, et al.. (2007). Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 42(1). 36–42. 66 indexed citations

20.

Man, Z., et al.. (2005). Osteoporosis inducida por corticoides. 111–139. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact